Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating AHB-171 Injection in a Phase I clinical trial to assess its safety, tolerability, immune response, and pharmacokinetics in both healthy adults and adults with chronic hepatitis B CHB. The study also aims to explore the preliminary effectiveness of AHB-171 in CHB participants. This trial includes two parts Part A with healthy participants and Part B with CHB participants receiving background treatment. Participants receive AHB-171 Injection or placebo via subcutaneous injection. CHB participants also continue stable treatment with nucleostide analogue NA orally. Part A focuses on single ascending doses in healthy adults, while Part B involves multiple ascending doses in CHB participants. The study monitors participants for up to 16 weeks in Part A and up to 48 weeks in Part B, assessing various safety and pharmacokinetic parameters. During the study, participants undergo laboratory tests, physical exams, vital sign checks, electrocardiograms, and ultrasound assessments. Researchers track adverse events and measure drug levels in the blood and urine, as well as immune responses against AHB-171. In CHB participants, viral markers and liver function tests are monitored to evaluate treatment effects. Participants are followed closely throughout the study duration, which may last up to 48 weeks depending on the group.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of LBL-024 in patients with advanced malignant tumors in a phase III clinical study. This study includes patients who have failed previous standard treatments, lack standard treatment options, or are not suitable for such treatments. The trial consists of two parts a phase IIIa dose escalation and pharmacokinetic expansion phase, and a phase IIb pivotal single-arm clinical study. Participants receive LBL-024 injections at the maximum tolerated dose every three weeks. The phase IIIa part focuses on dose escalation, safety, and preliminary efficacy, while the phase IIb part serves as a single-arm registry study to further assess the treatment. The study evaluates the drugs pharmacokinetic characteristics and immune response throughout treatment. During the study, participants are closely monitored for dose-limiting toxicities within three weeks of the first dose and maximum tolerated dose completion. Researchers assess objective response rate, adverse events, immunogenicity, disease control rate, and progression-free survival. Follow-up visits occur up to 30 days after treatment discontinuation or withdrawal. The total study duration extends until December 2026.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of combining selinexor with azacitidine and venetoclax in adults newly diagnosed with acute myeloid leukemia AML who have not received prior treatment. The study is a prospective, single-arm, multi-center clinical trial focusing on patients who are either ineligible for or refuse intensive chemotherapy. It is designed to gather data on how well this combination works and its safety profile in this patient group. Participants will receive selinexor orally at 60 mg on days 3, 10, and 17 azacitidine intravenously at 75 mgm2 on days 1-3, 8-9, and 15-16 and venetoclax orally starting at 100 mg on day 1, increasing to 200 mg on day 2, and 400 mg on days 3-14 within each 28-day treatment cycle. Those who achieve complete remission may undergo a transplant at any time, while others will continue treatment until the disease progresses or unacceptable side effects occur. During the study, participants will be closely monitored for treatment response and safety through assessments including remission rates up to about two years. Secondary measures include overall survival, response rates, minimal residual disease negativity, and recurrence-free survival over approximately four years. The total participation time varies based on individual outcomes, with ongoing evaluations to track effectiveness and side effects throughout the study period.
Actively Recruiting
Researchers are evaluating the drug ZL-1310 in people with extensive small cell lung cancer SCLC. This phase 1, open-label study aims to assess the safety, effectiveness, and how the body processes ZL-1310 alone and in combination with other drugs including Atezolizumab and Carboplatin. The study includes participants who have not received prior systemic treatment for SCLC or those with disease progression after chemotherapy. Participants may receive ZL-1310 alone, with Atezolizumab, or with both Atezolizumab and Carboplatin as induction therapy followed by maintenance treatment. The study includes different dosing levels established from earlier dose escalation and multiple arms to explore these combinations. Some participants may receive extended dosing based on emerging data and prior treatments. During the study, participants will undergo tumor biopsies or provide archived tumor tissue. Researchers will monitor safety through adverse event tracking up to 24 months, assess tumor responses using imaging scans, and measure pharmacokinetics of ZL-1310. The study also evaluates disease control rates and progression-free survival. Participation involves regular assessments and treatments over several months with follow-up to monitor outcomes.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a dual-endoscope assisted sentinel lymph node navigation surgery for patients with early gastric cancer. The goal is to assess this advanced surgical techniques ability to accurately identify and remove lymph nodes while minimizing complications. This prospective registry study is sponsored by Jilin University and focuses on treatment outcomes for this condition. Participants receive laparoscopic-endoscopic cooperative surgery LECS where, after eligibility confirmation and general anesthesia, a tracer dye is injected around the tumor to identify sentinel lymph nodes. The primary lesion is marked and removed through full-thickness resection, followed by closure of gastric wall defects. Sentinel lymph nodes are examined during surgery if cancer is detected in these lymph nodes, a more extensive gastrectomy is performed. Otherwise, the procedure concludes with drainage tube placement. During the study, participants undergo perioperative monitoring to track complications for one month after surgery. The number of lymph nodes removed is also counted one week post-surgery. The study involves a single treatment period with no placebo or comparison group. Participants may expect regular assessments related to their surgical recovery and lymph node evaluation, contributing valuable data on this surgical approachs safety and precision.
Actively Recruiting
Researchers are conducting a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in male patients aged 18 to 75 with atherosclerotic cardiovascular and cerebrovascular diseases and mild to moderate erectile dysfunction. The study aims to understand how YN001 might affect erectile function and vascular health in these patients. Participants are assigned to one of two groups one receiving YN001 20 mg plus 5% glucose injection once weekly, and the other receiving a placebo 5% glucose injection once weekly. Treatments are administered for 12 weeks. The trial uses a parallel study model with quadruple masking to compare the effects of the active drug versus placebo. During the study, participants will be evaluated through questionnaires assessing erectile function and undergo peripheral ultrasound to measure carotid artery thickness at baseline and after 12 weeks. Researchers will monitor adverse events for up to 16 weeks. The main outcomes measured include changes in erectile function scores and carotid artery intima-media thickness, with the trial expected to complete by December 2026.
Actively Recruiting
Researchers are conducting a phase 3, randomized, double-blind study to evaluate the effectiveness of Ivonescimab combined with mFOLFOX6 versus Bevacizumab combined with mFOLFOX6 for the first-line treatment of metastatic colorectal cancer. The trial includes patients who have not previously received systemic therapy for metastatic disease and aims to compare these treatments in a controlled setting. Participants will be randomly assigned to one of two treatment groups Ivonescimab plus mFOLFOX6 or Bevacizumab plus mFOLFOX6. Both treatments are given by intravenous infusion every two weeks for up to eight cycles. After these initial treatment cycles, maintenance therapy with Ivonescimab or Bevacizumab combined with Leucovorin and 5-Fluorouracil will be administered every two weeks for up to two years. Throughout the study, participants will undergo regular assessments to monitor disease progression using standardized imaging criteria. Researchers will evaluate progression-free survival as the primary outcome over approximately 2.5 years, alongside secondary outcomes including overall survival, tumor response rate, duration of response, and adverse events over up to 4 years. Study-related care and follow-up will be conducted during this period to assess treatment effects and safety.
Actively Recruiting
Researchers are studying MCLA-129, a human bispecific antibody targeting EGFR and cMet, in patients with advanced solid tumors, including non-small cell lung cancer NSCLC, head and neck cancer, and colorectal cancer. This multi-center, open-label Phase III study aims to evaluate the safety, pharmacokinetics, and antitumor activity of MCLA-129. The study includes patients with tumors that have progressed after standard treatments or are intolerant to them. The study has two parts Part I involves dose escalation and dose expansion to determine safe and effective dose levels of MCLA-129 administered by intravenous infusion every one or two weeks. Part II is a cohort expansion phase assessing efficacy, safety, and pharmacokinetics at the recommended Phase II dose in groups of patients with specific biomarker profiles, such as EGFR mutations or MET amplification. Participants will receive MCLA-129 infusions in 28-day cycles and undergo regular assessments including tumor measurements, safety monitoring, and pharmacokinetic testing. Primary outcomes include dose-limiting toxicity, maximum tolerated dose, overall response rate, and treatment-emergent adverse events. Secondary outcomes measure drug levels, response duration, progression-free survival, and overall survival. Follow-up continues for approximately two years after treatment initiation to monitor effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of plozasiran in adults with severe hypertriglyceridemia who have experienced at least two prior acute pancreatitis episodes, with at least one occurring within the last year before screening. This phase 3, randomized, double-blind study aims to understand how plozasiran impacts the risk of acute pancreatitis in this high-risk population. Participants will be randomly assigned to receive either plozasiran 25 mg or a matching placebo through subcutaneous injections every three months during the double-blind treatment period. They are advised to maintain a low-fat diet and continue their usual lipid-lowering medications. After finishing this period or experiencing an acute pancreatitis event, participants may enter a 12-month open-label extension where all receive plozasiran injections every three months. Throughout the study, participants will undergo regular assessments including measuring the time to the first acute pancreatitis event, changes in fasting triglyceride levels, and patient-reported health and productivity questionnaires. Safety will be monitored by tracking adverse events and cardiovascular outcomes. The study duration spans up to approximately 50 months for the double-blind phase, followed by a 12-month extension, with ongoing evaluations to understand the treatments impact.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the effects of transcranial current stimulation on insomnia disorder, a common sleep problem. This study aims to understand how this noninvasive device impacts brain activity and neurobiological changes related to sleep. Although this treatment is promising, its specific effects on brain structure and function during sleep are still unclear. Participants will receive either active or sham transcranial current stimulation for 14 consecutive days. Each session lasts 20 minutes with a 1.1-mA current, including 30 seconds of gradual current changes at the start and end. The sham group will wear the device without any stimulation. The study is randomized and quadruple-blinded to compare the outcomes between these two groups. During the study, participants will be assessed at 2 weeks and 3 months after treatment. Researchers will measure brain blood flow signals, brain connectivity, and other brain activity markers using imaging techniques. They will also evaluate insomnia severity, anxiety, depression, sleep quality through polysomnography, and biological factors such as hormone and protein levels in the blood. This comprehensive monitoring will help understand the treatments effects and safety over time.